PRS25 THE IMPACT TRIAL: IS SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) COST-EFFECTIVE VERSUS DUAL THERAPY WITH INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST (FF/VI) IN PATIENTS WITH COPD IN SPAIN?
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.2515
https://www.valueinhealthjournal.com/article/S1098-3015(19)34893-4/fulltext
Section Title :
Section Order :
12203
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34893-4&doi=10.1016/j.jval.2019.09.2515